Percutaneous parathyroid ethanol ablation in patients with multiple endocrine neoplasia type 1

Mark W. Veldman, Carl C. Reading, Michael A. Farrell, Brian P. Mullan, Robert A. Wermers, Clive S. Grant, Geoff B. Thompson

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

OBJECTIVE. The objective of our study was to show the efficacy and safety of percutaneous ethanol ablation in managing recurrent primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1 (MEN1) after subtotal parathyroidectomy. CONCLUSION. Ethanol ablation is a viable alternative to reoperation for the management of recurrent primary hyperparathyroidism in patients with MEN1.

Original languageEnglish (US)
Pages (from-to)1740-1744
Number of pages5
JournalAmerican Journal of Roentgenology
Volume191
Issue number6
DOIs
StatePublished - Dec 1 2008

Keywords

  • Alcohol ablation
  • Ethanol ablation
  • Hypercalcemia
  • Hyperparathyroidism
  • Multiple endocrine neoplasia syndrome
  • Parathyroid gland

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Percutaneous parathyroid ethanol ablation in patients with multiple endocrine neoplasia type 1'. Together they form a unique fingerprint.

  • Cite this

    Veldman, M. W., Reading, C. C., Farrell, M. A., Mullan, B. P., Wermers, R. A., Grant, C. S., & Thompson, G. B. (2008). Percutaneous parathyroid ethanol ablation in patients with multiple endocrine neoplasia type 1. American Journal of Roentgenology, 191(6), 1740-1744. https://doi.org/10.2214/AJR.07.3431